The eyes are not just instruments of sight—they are intricate mirrors of the body’s health. Every vein, artery, and nerve in the retina tells a story, a map of potential conditions that often remain hidden until advanced stages. Harnessing this profound insight, identifeye HEALTH is transforming healthcare by developing non-invasive, AI-driven retinal imaging technologies that detect early signs of disease, offering patients a chance to act before illness progresses.

Nestled within the thriving ecosystem of the 4Catalyzer accelerator, identifeye HEALTH benefits from the collective knowledge of over 300 scientists and engineers, along with more than $700 million in funding. With offices spanning Guilford, Connecticut, New York City, and Palo Alto, the company thrives in innovation hubs that foster collaboration, research, and rapid product development.

Guided by the pioneering spirit of 4Catalyzer founder Jonathan Rothberg—renowned for next-generation DNA sequencing and the ultrasound-on-a-chip breakthrough through Butterfly Network—identifeye HEALTH has positioned itself at the forefront of health diagnostics. The company’s mission is clear: to leverage ocular insight to create a revolutionary, accessible, and personalized approach to disease detection.

Harnessing the Power of the Retina

The retina, as the innermost layer of the eye, provides a unique and direct window into systemic health. Each individual’s retina carries subtle markers of cardiovascular function, metabolic status, neurological health, and more. Through advanced retinal imaging paired with sophisticated machine learning algorithms, identifeye HEALTH transforms these intricate patterns into actionable data, enabling early detection of conditions that might otherwise go unnoticed.

One of the company’s immediate focal points is diabetic retinopathy, a leading cause of preventable blindness in adults. By offering a reliable, non-invasive screening solution, identifeye HEALTH is breaking down accessibility barriers and helping ensure timely diagnosis for populations that are often underserved in traditional screening programs.

AI-Powered Insights Beyond Ocular Health

Identifeye HEALTH’s technology extends far beyond eye-related conditions. Using artificial intelligence, retinal scans can indicate broader health risks—ranging from cardiovascular disease and obesity-related complications to neurological disorders and systemic inflammation. This holistic approach allows healthcare providers to gain a multi-dimensional view of a patient’s health through a single, non-invasive test, redefining the scope and impact of preventive care.

At its core, identifeye HEALTH is committed to making healthcare more equitable. By leveraging AI and advanced retinal imaging, the company seeks to democratize access to early diagnostics, ensuring that individuals from diverse backgrounds can benefit from high-quality, personalized health insights. Technology is used not only to improve detection accuracy but to bridge gaps in healthcare accessibility, enabling timely intervention and fostering better outcomes for communities worldwide.

Empowering Patients with Proactive Solutions

The company has developed a suite of machine learning products that revolutionize health monitoring and disease prevention. From diabetic retinopathy screening to future diagnostic tools aimed at multiple health conditions, identifeye HEALTH envisions a world where early detection is simple, precise, and actionable. Its tools empower patients to take an active role in their health, promoting proactive interventions rather than reactive treatment.

Collaboration is central to the company’s approach. By partnering with healthcare providers, researchers, and technology experts, identifeye HEALTH leverages collective expertise to refine its tools, ensuring accuracy and clinical relevance while delivering meaningful improvements in patient care.

Shaping the Future of Diagnostics

With Vicky at the helm, identifeye HEALTH is redefining the potential of retinal imaging, blending technology and patient-centered design to offer non-invasive, precise, and accessible diagnostics. The company’s vision extends beyond eye health, positioning retinal scans as a gateway for detecting a broad range of systemic conditions, empowering healthcare providers and patients alike.

Every initiative at identifeye HEALTH reflects a commitment to proactive care, early intervention, and equitable access to health solutions. By combining AI, machine learning, and sophisticated imaging, the company is not only creating new possibilities in diagnostics but also reshaping the way healthcare systems approach prevention and wellness.

identifeye HEALTH exemplifies the convergence of innovation, vision, and purpose. Its work demonstrates that the eyes are more than instruments of vision—they are a powerful diagnostic tool that can transform healthcare delivery. By making early detection intuitive, precise, and accessible, identifeye HEALTH empowers individuals to understand their health like never before and equips healthcare providers with actionable insights to improve outcomes.

Through continuous innovation, strategic partnerships, and a focus on equity, identifeye HEALTH is redefining what is possible in diagnostics. The company is charting a course toward a future where technology meets humanity, where early detection is a standard, and where proactive healthcare is within reach for everyone.

The Visionary Leader Upfront

Vasiliki (Vicky) Demas, PhD, is the Founder, CEO, and Board Member of identifeye HEALTH, bringing over two decades of experience in team building, healthcare product development, and program management. With a Ph.D. in Chemical Engineering from UC Berkeley, Vicky has a proven track record of success in launching innovative healthcare solutions.

Prior to her role at identifeye HEALTH, Vicky played a pivotal role in advancing new products at GRAIL, a cancer screening company, where she managed scientific and technology portfolios and spearheaded cross-functional competitive intelligence initiatives. She was instrumental in developing the core platform technology for GRAIL's multi-cancer early detection test, Galleri, and led post-diagnostic efforts.

Vicky's career includes being a founding member of the Google Life Sciences (GLS) team within Google [x], which later evolved into Verily. At Verily, she led various teams and projects in diagnostics, medical devices, and translational laboratory science, contributing to the establishment of multidisciplinary science and engineering programs.

Prior to her tenure at Verily, Vicky held significant roles at T2 Biosystems and gained experience in engineering consulting. She holds over 20 patents and has authored numerous publications spanning multiple disciplines. Vicky completed her postdoctoral fellowship at Lawrence Berkeley and Livermore National Labs, further enriching her expertise in chemical engineering.

“We’re steadfastly patient-first, and believe healthcare should meet patients where they are. Our products serve both patients and providers, but we always keep patient needs at the center of our solutions.”